Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Alvocidib + Cytarabine + Daunorubicin |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Alvocidib | flavopiridol|HMR 1275|L-868275|DSP-2033 | CDK Inhibitor (Pan) 3 CDK1 Inhibitor 13 CDK2 Inhibitor 31 CDK4 Inhibitor 18 CDK6 Inhibitor 6 CDK7 Inhibitor 16 CDK9 Inhibitor 21 | Alvocidib (flavopiridol) is an inhibitor of CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9, which may induce cell cycle arrest and apoptosis in cancer cells (PMID: 12165651, PMID: 8674031, PMID: 24470357). | |
| Cytarabine | Cytosar-U | Ara-C | Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309). | |
| Daunorubicin | Cerubidine | Rubidomycin|daunomycin hydrochloride|rubomycin C|Acetyladriamycin | Chemotherapy - Anthracycline 13 | Cerubidine (daunorubicin) is an anthracycline, which inhibits DNA replication and repair. Cerubidine (daunorubicin) is FDA approved for AML and MLL (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03298984 | Phase I | Alvocidib + Cytarabine + Daunorubicin | Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | Completed | USA | 0 |